NCT04546945Recruiting
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Resident Doctor at Clinical Pathology Department
Source: ClinicalTrials.gov · Last updated 18 Mar 2026
Brief summary (registry, in English)
CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 38 (estimated)
- First submitted
- 3 Sept 2020
- Start date
- 20 Mar 2027
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Asmaa Hassan mohamed Abdel Mawjoud
- Diseases
- Childhood cancers
- NCT number
- NCT04546945
What you commit to
- Study type: Observational
- Planned participants: 38
- From 20 Mar 2027 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with hematologic disorders other than hematologic malignancies.
Who the study is looking for
- Patients with hematologic malignancies.
- Newly diagnosed
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assiut University Coordinator of this site? Confirm its status | Asyut | Egypt | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.